Streetbeat News

EOLS

Evolus, Inc.

https://www.evolus.com

Industry

Drug Manufacturers - Specialty & Generic

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Open

11.97

Mkt cap

767M

Volume

1.2M

High

12.13

P/E Ratio

-13.31

52-wk high

17.82

Low

11.37

Div yield

N/A

52-wk low

9.24

Evolus (EOLS) is showing signs of a potential turnaround with a hammer chart pattern indicating support and Wall Street analysts revising earnings estimates higher.

Portfolio Pulse from

November 18, 2024 | 4:00 pm

Evolus (EOLS) has experienced a significant decline of 29.8% over the past four weeks, placing it in oversold territory. The selling pressure may have subsided, and with Wall Street analysts raising earnings estimates, a trend reversal could be on the horizon.

Portfolio Pulse from

November 14, 2024 | 3:45 pm

Evolus, Inc. (EOLS) reported a Q3 loss of $0.19 per share, missing the Zacks Consensus Estimate of a $0.08 loss. This is consistent with the loss reported a year ago.

Portfolio Pulse from

November 07, 2024 | 12:45 am

Evolus, Inc. (NASDAQ: EOLS) reported its financial results for Q3 2024, highlighting significant growth and momentum in its aesthetic portfolio.

Portfolio Pulse from

November 06, 2024 | 9:30 pm

HC Wainwright & Co. has reiterated its Buy rating on Evolus (NASDAQ:EOLS) and maintained a price target of $27.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 10:44 am

Evolus has received EU approval for its Estyme Injectable Hyaluronic Acid Gels under the new Medical Device Regulation, with a broader launch planned for late 2025.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 6:02 pm

In the last three months, five analysts have rated Evolus (NASDAQ:EOLS), with most being bullish. The average 12-month price target increased to $23.6, with a high of $27.00 and a low of $20.00. Evolus, a performance beauty company, has shown a 35.59% revenue growth rate but faces challenges with high debt and low ROE and ROA.

Portfolio Pulse from Benzinga Insights

October 03, 2024 | 1:01 pm

HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating for Evolus (NASDAQ:EOLS) and maintained a price target of $27.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 11:18 am

Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Evolus (NASDAQ:EOLS).

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:24 pm

Evolus (NASDAQ:EOLS) has received diverse analyst ratings over the past three months, with a majority being bullish. The average 12-month price target has increased by 4.6% to $22.75. Analysts have adjusted their ratings and price targets, reflecting positive sentiment. Evolus, a performance beauty company, has shown strong revenue growth but faces challenges with high debt and low ROE and ROA.

Portfolio Pulse from Benzinga Insights

September 13, 2024 | 4:01 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.